atrial cardiomyocytes Search Results


93
StemBioSys cardiomyocytes

Cardiomyocytes, supplied by StemBioSys, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/atrial+cardiomyocytes/Human+Atrial+iPS+Cardiomyocytes/pmc10320609-219-19-7
Average 93 stars, based on 1 article reviews
cardiomyocytes - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

94
Axol Bioscience atrial cardiomyocytes
Inositol trisphosphate (IP 3 ) pathway is active in human atrial induced pluripotent stem cells (iPSCs) as shown using multielectrode array. A : representative averaged multielectrode array (MEA) field action potential waveforms from control (dimethylsulfoxide, DMSO; n = 7), phenylephrine (PE; 30 μM; n = 11), and PE (1 or 30 μM) in the presence of either H89 (1 μM; n = 7) or MDL-12330A (3 μM; n = 1–10). B : effect of H89 (1 μM) and MDL-12330A (3 μM) on the beat rate of human iPSCs-derived atrial <t>cardiomyocytes</t> (hiPSC-ACMs) in response to PE at concentrations of 1–30 μM (DMSO, n = 7; H89, n = 7; MDL-12330A, n = 10). Data are represented as means ± SD. * P < 0.05, ** P < 0.01, and *** P < 0.001, 2-way repeated-measures ANOVA followed by Sidak’s multiple comparisons. IP 3 , inositol (1,4,5)-trisphosphate.
Atrial Cardiomyocytes, supplied by Axol Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/atrial+cardiomyocytes/Human+iPSC-Derived+Atrial+Cardiomyocytes/pmc11482242-77-10-14
Average 94 stars, based on 1 article reviews
atrial cardiomyocytes - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

90
Johns Hopkins HealthCare atrial ttn gfp cardiomyocytes
a Flow cytometry plots of <t>GFP</t> + <t>TTN-GFP</t> hiPSC-CMs following CM-AI purification stained for cardiac troponin T (cTnT-APC). b Flow cytometry of untagged 19.9.11 hiPSC-CMs stained with cTnT-APC following CM-AI purification. c Summary of cTnT+ cell percentages from three independent differentiations using TTN-GFP and 19.9.11 hiPSC lines ( n = 3 per line). Average purity was 92.0 ± 1.0% and 94.3 ± 7.2%, respectively. No residual expression of pluripotency markers (NANOG, POU5F1) detected post-CM-AI processing (qRT-PCR; Supplementary Table ). Data are mean ± s.d.
Atrial Ttn Gfp Cardiomyocytes, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/atrial+cardiomyocytes/atrial+ttn+gfp+cardiomyocytes/pmc12075813-187-0-19
Average 90 stars, based on 1 article reviews
atrial ttn gfp cardiomyocytes - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
The Company of Biologists atrial cardiomyocytes
a Flow cytometry plots of <t>GFP</t> + <t>TTN-GFP</t> hiPSC-CMs following CM-AI purification stained for cardiac troponin T (cTnT-APC). b Flow cytometry of untagged 19.9.11 hiPSC-CMs stained with cTnT-APC following CM-AI purification. c Summary of cTnT+ cell percentages from three independent differentiations using TTN-GFP and 19.9.11 hiPSC lines ( n = 3 per line). Average purity was 92.0 ± 1.0% and 94.3 ± 7.2%, respectively. No residual expression of pluripotency markers (NANOG, POU5F1) detected post-CM-AI processing (qRT-PCR; Supplementary Table ). Data are mean ± s.d.
Atrial Cardiomyocytes, supplied by The Company of Biologists, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/atrial+cardiomyocytes/atrial+cardiomyocytes/pm11076755-9-3-22
Average 90 stars, based on 1 article reviews
atrial cardiomyocytes - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Axiogenesis atrial cardiomyocytes
a Flow cytometry plots of <t>GFP</t> + <t>TTN-GFP</t> hiPSC-CMs following CM-AI purification stained for cardiac troponin T (cTnT-APC). b Flow cytometry of untagged 19.9.11 hiPSC-CMs stained with cTnT-APC following CM-AI purification. c Summary of cTnT+ cell percentages from three independent differentiations using TTN-GFP and 19.9.11 hiPSC lines ( n = 3 per line). Average purity was 92.0 ± 1.0% and 94.3 ± 7.2%, respectively. No residual expression of pluripotency markers (NANOG, POU5F1) detected post-CM-AI processing (qRT-PCR; Supplementary Table ). Data are mean ± s.d.
Atrial Cardiomyocytes, supplied by Axiogenesis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/atrial+cardiomyocytes/atrial+cardiomyocytes/10__2217_slash_17460751__3__3__257-27-9-6
Average 90 stars, based on 1 article reviews
atrial cardiomyocytes - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Axiogenesis embryonic stem cell-derived pacemaker and atrial cardiomyocytes
a Flow cytometry plots of <t>GFP</t> + <t>TTN-GFP</t> hiPSC-CMs following CM-AI purification stained for cardiac troponin T (cTnT-APC). b Flow cytometry of untagged 19.9.11 hiPSC-CMs stained with cTnT-APC following CM-AI purification. c Summary of cTnT+ cell percentages from three independent differentiations using TTN-GFP and 19.9.11 hiPSC lines ( n = 3 per line). Average purity was 92.0 ± 1.0% and 94.3 ± 7.2%, respectively. No residual expression of pluripotency markers (NANOG, POU5F1) detected post-CM-AI processing (qRT-PCR; Supplementary Table ). Data are mean ± s.d.
Embryonic Stem Cell Derived Pacemaker And Atrial Cardiomyocytes, supplied by Axiogenesis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/atrial+cardiomyocytes/embryonic+stem+cell+derived+pacemaker+and+atrial+cardiomyocytes/pm15659535-11-9-35
Average 90 stars, based on 1 article reviews
embryonic stem cell-derived pacemaker and atrial cardiomyocytes - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

N/A
Starting material Cord blood CD34+ cells Donor gender Male Donor age at sampling Newborn HLA serotype A29 A68, B38 (Bw4) B44 (Bw4), Cw8 Cw12 Karyotype Normal
  Buy from Supplier

Image Search Results


Journal: iScience

Article Title: High-throughput longitudinal electrophysiology screening of mature chamber-specific hiPSC-CMs using optical mapping

doi: 10.1016/j.isci.2023.107142

Figure Lengend Snippet:

Article Snippet: Human ECM-coated cell culture plates (CELLvo MatrixPlus, StemBioSys, Inc.) promoted significant maturation of hiPSC-CM toward rod-shaped cells reminiscent of cardiomyocytes isolated from adult mammalian hearts ( and ). hiPSC-CM sarcomere length was longer and more organized in cells maintained on MatrixPlus-human ECM ( C and 1D).

Techniques: Virus, Plasmid Preparation, Recombinant, Membrane, Isolation, Software

Inositol trisphosphate (IP 3 ) pathway is active in human atrial induced pluripotent stem cells (iPSCs) as shown using multielectrode array. A : representative averaged multielectrode array (MEA) field action potential waveforms from control (dimethylsulfoxide, DMSO; n = 7), phenylephrine (PE; 30 μM; n = 11), and PE (1 or 30 μM) in the presence of either H89 (1 μM; n = 7) or MDL-12330A (3 μM; n = 1–10). B : effect of H89 (1 μM) and MDL-12330A (3 μM) on the beat rate of human iPSCs-derived atrial cardiomyocytes (hiPSC-ACMs) in response to PE at concentrations of 1–30 μM (DMSO, n = 7; H89, n = 7; MDL-12330A, n = 10). Data are represented as means ± SD. * P < 0.05, ** P < 0.01, and *** P < 0.001, 2-way repeated-measures ANOVA followed by Sidak’s multiple comparisons. IP 3 , inositol (1,4,5)-trisphosphate.

Journal: American Journal of Physiology - Heart and Circulatory Physiology

Article Title: Activation of IP 3 R in atrial cardiomyocytes leads to generation of cytosolic cAMP

doi: 10.1152/ajpheart.00152.2024

Figure Lengend Snippet: Inositol trisphosphate (IP 3 ) pathway is active in human atrial induced pluripotent stem cells (iPSCs) as shown using multielectrode array. A : representative averaged multielectrode array (MEA) field action potential waveforms from control (dimethylsulfoxide, DMSO; n = 7), phenylephrine (PE; 30 μM; n = 11), and PE (1 or 30 μM) in the presence of either H89 (1 μM; n = 7) or MDL-12330A (3 μM; n = 1–10). B : effect of H89 (1 μM) and MDL-12330A (3 μM) on the beat rate of human iPSCs-derived atrial cardiomyocytes (hiPSC-ACMs) in response to PE at concentrations of 1–30 μM (DMSO, n = 7; H89, n = 7; MDL-12330A, n = 10). Data are represented as means ± SD. * P < 0.05, ** P < 0.01, and *** P < 0.001, 2-way repeated-measures ANOVA followed by Sidak’s multiple comparisons. IP 3 , inositol (1,4,5)-trisphosphate.

Article Snippet: For multielectrode array (MEA) experiments, human induced pluripotent stem cells-derived atrial cardiomyocytes (hiPSC-ACMs) (ax2518, Axol Bioscience, UK) were cultured at 5.0 × 10 5 cells/well on a 768-channel 48-well Axion Cytoview MEA 48 plate (M768-tMEA-48B, Axion Biosystems, USA) coated with Axol’s Fibronectin Coating Solution (ax0049, Axol Bioscience, UK) at 37°C in a 5% CO 2 –95% air atmosphere.

Techniques: Control, Derivative Assay

a Flow cytometry plots of GFP + TTN-GFP hiPSC-CMs following CM-AI purification stained for cardiac troponin T (cTnT-APC). b Flow cytometry of untagged 19.9.11 hiPSC-CMs stained with cTnT-APC following CM-AI purification. c Summary of cTnT+ cell percentages from three independent differentiations using TTN-GFP and 19.9.11 hiPSC lines ( n = 3 per line). Average purity was 92.0 ± 1.0% and 94.3 ± 7.2%, respectively. No residual expression of pluripotency markers (NANOG, POU5F1) detected post-CM-AI processing (qRT-PCR; Supplementary Table ). Data are mean ± s.d.

Journal: Communications Biology

Article Title: AI-guided laser purification of human iPSC-derived cardiomyocytes for next-generation cardiac cell manufacturing

doi: 10.1038/s42003-025-08162-0

Figure Lengend Snippet: a Flow cytometry plots of GFP + TTN-GFP hiPSC-CMs following CM-AI purification stained for cardiac troponin T (cTnT-APC). b Flow cytometry of untagged 19.9.11 hiPSC-CMs stained with cTnT-APC following CM-AI purification. c Summary of cTnT+ cell percentages from three independent differentiations using TTN-GFP and 19.9.11 hiPSC lines ( n = 3 per line). Average purity was 92.0 ± 1.0% and 94.3 ± 7.2%, respectively. No residual expression of pluripotency markers (NANOG, POU5F1) detected post-CM-AI processing (qRT-PCR; Supplementary Table ). Data are mean ± s.d.

Article Snippet: Atrial TTN GFP cardiomyocytes were differentiated, laser-purified, and cryopreserved at the University of Michigan and then shipped overnight to Johns Hopkins University.

Techniques: Flow Cytometry, Purification, Staining, Expressing, Quantitative RT-PCR

a Post-thaw viability was similar between two hiPSC lines tested (TTN-GFP hiPSC-CM = 74.3 ± 7.4; 19.9.11 hiPSC-CM = 61.7 ± 2.9%, n = 3 separate batches per group). b Time-lapse imaging was used to quantify hiPSC-CM 2D monolayer formation kinetics following thaw, data is mean ± standard deviation at each time point. c Phase contrast and GFP images for each cell line tested in panel b on day 3.5 post thaw. d , e Representative calcium transient recordings from each hiPSC line at baseline and with isoproterenol (ISO, 200 nM) treatment. f Each cell line hiPSC-CMs responded to ISO with increased beat rate (TTN-GFP hiPSC-CM baseline = 68.9 ± 8.1; +ISO = 93.3 ± 10.3 bpm, n = 6) (19.9.11 hiPSC-CM baseline = 100.3 ± 15.6; +ISO = 130.0 ± 20.6bpm, n = 6). Paired t -test, *** P = 0.0001. g Each cell line hiPSC-CMs responded to 200 nM ISO with increased calcium wave propagation velocity (TTN-GFP hiPSC-CM baseline = 33.7 ± 5.9; +ISO = 46.9 ± 4.6 cm/s, n = 6) (19.9.11 hiPSC-CM baseline = 30.1 ± 3.4; +ISO = 37.2 ± 6.3 cm/s, n = 6). Paired t -test, *** P = 0.0003; ** P = 0.04.

Journal: Communications Biology

Article Title: AI-guided laser purification of human iPSC-derived cardiomyocytes for next-generation cardiac cell manufacturing

doi: 10.1038/s42003-025-08162-0

Figure Lengend Snippet: a Post-thaw viability was similar between two hiPSC lines tested (TTN-GFP hiPSC-CM = 74.3 ± 7.4; 19.9.11 hiPSC-CM = 61.7 ± 2.9%, n = 3 separate batches per group). b Time-lapse imaging was used to quantify hiPSC-CM 2D monolayer formation kinetics following thaw, data is mean ± standard deviation at each time point. c Phase contrast and GFP images for each cell line tested in panel b on day 3.5 post thaw. d , e Representative calcium transient recordings from each hiPSC line at baseline and with isoproterenol (ISO, 200 nM) treatment. f Each cell line hiPSC-CMs responded to ISO with increased beat rate (TTN-GFP hiPSC-CM baseline = 68.9 ± 8.1; +ISO = 93.3 ± 10.3 bpm, n = 6) (19.9.11 hiPSC-CM baseline = 100.3 ± 15.6; +ISO = 130.0 ± 20.6bpm, n = 6). Paired t -test, *** P = 0.0001. g Each cell line hiPSC-CMs responded to 200 nM ISO with increased calcium wave propagation velocity (TTN-GFP hiPSC-CM baseline = 33.7 ± 5.9; +ISO = 46.9 ± 4.6 cm/s, n = 6) (19.9.11 hiPSC-CM baseline = 30.1 ± 3.4; +ISO = 37.2 ± 6.3 cm/s, n = 6). Paired t -test, *** P = 0.0003; ** P = 0.04.

Article Snippet: Atrial TTN GFP cardiomyocytes were differentiated, laser-purified, and cryopreserved at the University of Michigan and then shipped overnight to Johns Hopkins University.

Techniques: Imaging, Standard Deviation

a Cryopreserved TTN-GFP atrial hiPSC-CMs phase contrast and GFP images, 20×. b Zoomed image of sarcomere structures in hiPSC-CMs. c Representative time-space plots indicate functional monolayer electrophysiological activations across the width of each well of the 96-well plate (9 mm diameter). Rolipram increased hiPSC-CM monolayer beat rate. d Representative calcium transient traces indicating the effect of rolipram to increase calcium transient amplitude. e Rolipram increased 2D monolayer beat rate (VEH = 80.0 ± 11.8; 1.0 µM Rolipram = 113.3 ± 33.0; 10.0 µM Rolipram = 129.2 ± 9.4 bpm, n = 8 per group). One way ANOVA, multiple comparisons, * P = 0.01; *** P = 0.0004. f Rolipram increased calcium transient amplitude (VEH = 0.53 ± 0.17; 1.0 µM Rolipram = 0.72 ± 0.40; 10.0 µM Rolipram=1.22 ± 0.50 ∆F/F 0 , n = 8 per group). One way ANOVA, multiple comparisons, ** P = 0.004. g Rolipram increased calcium impulse conduction velocity (VEH = 23.5 ± 4.1; 1.0 µM Rolipram = 30.3 ± 17.6; 10.0 µM Rolipram = 47.9 ± 20.4 cm/s, n = 8 per group). One way ANOVA, Brown-Forsythe and Welch tests, multiple comparisons, * P = 0.02.

Journal: Communications Biology

Article Title: AI-guided laser purification of human iPSC-derived cardiomyocytes for next-generation cardiac cell manufacturing

doi: 10.1038/s42003-025-08162-0

Figure Lengend Snippet: a Cryopreserved TTN-GFP atrial hiPSC-CMs phase contrast and GFP images, 20×. b Zoomed image of sarcomere structures in hiPSC-CMs. c Representative time-space plots indicate functional monolayer electrophysiological activations across the width of each well of the 96-well plate (9 mm diameter). Rolipram increased hiPSC-CM monolayer beat rate. d Representative calcium transient traces indicating the effect of rolipram to increase calcium transient amplitude. e Rolipram increased 2D monolayer beat rate (VEH = 80.0 ± 11.8; 1.0 µM Rolipram = 113.3 ± 33.0; 10.0 µM Rolipram = 129.2 ± 9.4 bpm, n = 8 per group). One way ANOVA, multiple comparisons, * P = 0.01; *** P = 0.0004. f Rolipram increased calcium transient amplitude (VEH = 0.53 ± 0.17; 1.0 µM Rolipram = 0.72 ± 0.40; 10.0 µM Rolipram=1.22 ± 0.50 ∆F/F 0 , n = 8 per group). One way ANOVA, multiple comparisons, ** P = 0.004. g Rolipram increased calcium impulse conduction velocity (VEH = 23.5 ± 4.1; 1.0 µM Rolipram = 30.3 ± 17.6; 10.0 µM Rolipram = 47.9 ± 20.4 cm/s, n = 8 per group). One way ANOVA, Brown-Forsythe and Welch tests, multiple comparisons, * P = 0.02.

Article Snippet: Atrial TTN GFP cardiomyocytes were differentiated, laser-purified, and cryopreserved at the University of Michigan and then shipped overnight to Johns Hopkins University.

Techniques: Functional Assay